EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis

Michael Abbott, Mandy Ryan, Rodolfo Hernández, Lynda McKenzie, Sebastian Heidenreich, Lynne Hocking, Caroline Clark, Morad Ansari, David Moore, Anne Lampe, Ruth McGowan, Jonathan Berg und 1 weitere

The European Journal of Health Economics · 2025-04 · 26 (3) · 503-512

DOI: 10.1007/s10198-024-01717-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The European Journal of Health Economics, online erschienen am 09.09.2024. Verfasst von Michael Abbott und 12 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics Research Unit, University of Aberdeen, Aberdeen, UK. Michael.abbott@abdn.ac.uk. Hauptthemen laut MEDLINE: Rare Diseases, Genetic Testing, Developmental Disabilities, Whole Genome Sequencing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chief Scientist Office, Scottish Government Health and Social Care Directorate.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study aims to evaluate the cost effectiveness of genetic and genomic testing strategies for the diagnosis of rare developmental disorders in NHS Scotland.

Methods

Six genetic and genomic testing strategies were evaluated using a decision tree model. First-line, second-line and last-resort trio genome sequencing (GS), and second-line and last-resort trio exome sequencing (ES) were compared with standard genetic testing. The cost effectiveness of each strategy was expressed in terms of incremental cost per additional diagnosis. The impact of uncertainty on cost-effectiveness results was explored using deterministic and probabilistic sensitivity analysis.

Results

2nd-line ES was a cost-saving option, increasing diagnostic yield by 13.9% and decreasing cost by £1027 per trio compared to standard genetic testing. Compared to ES, strategies involving GS increased costs significantly, with only a moderate or zero improvement in diagnostic yield. Sensitivity analysis indicated that significant reductions in cost or improvements in diagnostic yield are required before 1st-line GS becomes cost effective.

Conclusion

2nd-line ES (after chromosomal microarray; replacing gene panel testing) for the diagnosis of developmental disorders is a cost-saving option for the Scottish NHS. Ongoing economic evaluation is required to monitor the evolving cost and diagnostic yield of GS and ES over time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rare DiseasesGenetic TestingDevelopmental DisabilitiesWhole Genome SequencingHumansScotlandCost-Benefit AnalysisDecision TreesExome SequencingState MedicineCost-Effectiveness Analysis

Stichwörter der Autor:innen

Cost effectivenessEconomic evaluationGeneticsGenomicsRare conditions

Autor:innen und Institutionen

  • Health Economics Research Unit, University of Aberdeen, Aberdeen, UK. Michael.abbott@abdn.ac.uk.
  • Health Economics Research Unit, University of Aberdeen, Aberdeen, UK.
  • Evidera Inc., London, UK.
  • Department of Medical Genetics, University of Aberdeen, Aberdeen, UK.
  • NHS Grampian Regional Genetics Service, Aberdeen Royal Infirmary, Aberdeen, UK.
  • South East Scotland Genetic Service, NHS Lothian, Edinburgh, UK.

Förderung

  • Chief Scientist Office, Scottish Government Health and Social Care Directorate

Zitieren

APA

Abbott, M., Ryan, M., Hernández, R., McKenzie, L., Heidenreich, S., Hocking, L., Clark, C., Ansari, M., Moore, D., Lampe, A., McGowan, R., Berg, J., & Miedzybrodzka, Z. (2025). Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis. The European Journal of Health Economics, 26(3), 503-512. https://doi.org/10.1007/s10198-024-01717-8

Vancouver

Abbott M, Ryan M, Hernández R, McKenzie L, Heidenreich S, Hocking L, et al. Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis. The European Journal of Health Economics. 2025;26(3):503-512. doi:10.1007/s10198-024-01717-8

BibTeX
@article{Abbott2025,
  author = {Abbott, Michael and Ryan, Mandy and Hernández, Rodolfo and McKenzie, Lynda and Heidenreich, Sebastian and Hocking, Lynne and Clark, Caroline and Ansari, Morad and Moore, David and Lampe, Anne and McGowan, Ruth and Berg, Jonathan and Miedzybrodzka, Zosia},
  title = {Should Scotland provide genome-wide sequencing for the diagnosis of rare developmental disorders? A cost-effectiveness analysis},
  journal = {The European Journal of Health Economics},
  year = {2025},
  volume = {26},
  number = {3},
  pages = {503--512},
  doi = {10.1007/s10198-024-01717-8}
}
Kostenlos starten →